The head of the U.S. Food and Drug Administration has been walking back comments about possible COVID-19 treatments since the Trump Administration announced emergency approval of blood plasma for hospitalized COVID-19 patients. The use of plasma was claimed to reduce deaths by 35%. Scientists who worked on the study say that statistic is false. The therapy is considered safe, but hasn’t been proven effective against the coronavirus. So how much stock should we put in this treatment?
Dr. Marc Klapholz, chair of the Department of Medicine at Rutgers Medical School and principal investigator on the use of convalescent plasma, joins Senior Correspondent Briana Vannozzi.